Candel Therapeutics, Inc.

CADL · Nasdaq · United States

Share price · CADL

$5.32-6.73 (-55.85%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.4M (1.0x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when CADL's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 13 Nov 2026-26.1%
  2. 3 Nov 2026+8.6%
  3. 11 Sep 2026-6.9%
  4. 13 Aug 2026+10.5%
  5. 4 May 2026+16.4%
  6. 20 Apr 2026+13.3%
  7. 17 Apr 2026+23.4%
  8. 20 Feb 2026-14.2%
  9. 20 Jan 2026-7.5%
  10. 16 Jan 2026+7.7%

    Nothing announced by CADL that day or the session before.

Share of unusual movement by asset

For each asset, the share of CADL's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Aglatimagene Besadenovec
events and moves
1330%
Other company news (earnings, financing, releases naming no asset)—16%
Sessions with no dated event—54%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
Herpes simplex virus thymidine kinase (HSV-tk) gene productGene therapy / editing
Non-Small Cell Lung Cancer

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
Aglatimagene BesadenovecPhase 2Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)
Est. primary completion 2027-02 · NCT07332000 · CT.gov ↗
What to watch
2031 (1)
October 2031 (1)
Aglatimagene BesadenovecPhase 3Non-squamous, Non-Small Cell Lung Cancer
Est. primary completion 2031-10-22 · NCT07660094 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 May 2025Topline resultAglatimagene BesadenovecPhase 3 of aglatimagene besadenovec (CAN-2409) in localized prostate cancer improves disease-free survival
Candel Therapeutics, Inc. · Source ↗
11 December 2024Topline resultAglatimagene BesadenovecPhase 3 prostate cancer trial meets primary endpoint

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$16M$204M$22M-$23M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$20M$202M$39M-$17M operating cash flowreport ↗
2026-Q1—$9.8M$195M$8.9M-$18M operating cash flowreport ↗
2025-Q3—$8.5M$87M$11M-$10M operating cash flowreport ↗
2025-Q2—$7.0M$101M$4.8M-$8.9M operating cash flowreport ↗
2025-Q1—$4.0M$92M—-$8.6M operating cash flowreport ↗
2024-Q3—$5.4M$17M$11M-$6.6M operating cash flowreport ↗
2024-Q2—$5.0M$22M$22M-$6.2M operating cash flowreport ↗
2024-Q1—$4.1M$26M$8.2M-$8.4M operating cash flowreport ↗
2023-Q3—$5.8M$43M$8.4M-$8.8M operating cash flowreport ↗
2023-Q2—$5.9M$52M$9.6M-$7.2M operating cash flowreport ↗
2023-Q1—$5.5M$60M$8.8M-$11M operating cash flowreport ↗
2022-Q3<$0.1M$5.4M$77M$8.7M-$9.4M operating cash flowreport ↗
2022-Q2<$0.1M$5.0M$87M$4.2M-$7.1M operating cash flowreport ↗
2022-Q1<$0.1M$5.4M$95M$0.9M-$8.1M operating cash flowreport ↗
2021-Q3<$0.1M$5.3M$89M$16M-$6.9M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$30M$120M$9.6M-$38M operating cash flowreport ↗

Candel Therapeutics reported no revenue for the full year 2025. Research and development spend was $30.496M, up 57.9% YoY, and cash and cash equivalents totaled $119.731M as of December 31, 2025. The full-year net loss was $38.182M.

The company expects existing cash, together with proceeds from its February 2026 follow-on equity offering, to fund operations into Q1 2028. It plans to initiate a pivotal phase 3 trial of aglatimagene (CAN-2409) in non-small cell lung cancer in Q2 2026 and to submit a Biologics License Application for aglatimagene in localized prostate cancer in Q4 2026. The company also received IND clearance for linoserpaturev (CAN-3110) in recurrent high-grade glioma, entered a $130M term loan facility with Trinity Capital, and announced a $100M royalty funding agreement with RTW Investments. The pancreatic cancer program was paused.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$19M$103M$14M-$27M operating cash flowreport ↗
2023-FY$0.1M$25M$35M$9.5M-$34M operating cash flowreport ↗
2022-FY$0.1M$21M$70M$4.7M-$31M operating cash flowreport ↗
2021-FY$0.1M$15M$83M$9.0M-$22M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($3.0M), 5 sales ($3.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-03Ostrovsky Maria · General CounselAward / grant (derivative)315,000——Form 4
2026-09-30Manning Paul B · directorAward / grant (derivative)2,189$8.68$19KForm 4
2026-09-30PAPA JOSEPH C · directorAward / grant (derivative)1,325$8.68$11KForm 4
2026-09-30Loggia Nicoletta · directorAward / grant (derivative)380$8.68$3KForm 4
2026-09-11Tak Paul Peter · director, Chief Executive OfficerOpen-market sale59,379$10.46$621KForm 4
2026-09-10Tak Paul Peter · director, Chief Executive OfficerOption exercise125,000$1.55$194KForm 4
2026-09-10Tak Paul Peter · director, Chief Executive OfficerOpen-market sale220,866$11.50$2.5MForm 4
2026-09-10Tak Paul Peter · director, Chief Executive OfficerOption exercise (derivative)125,000——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 114 reporting institutions held 43.4M shares ($212.5M, 55.4% of shares outstanding).

#InstitutionSharesValue
1FMR LLC10,987,017$53.8M
2RTW INVESTMENTS, LP6,422,018$31.5M
3ACORN CAPITAL ADVISORS, LLC3,497,948$17.2M
4BlackRock, Inc.3,109,042$15.2M
5Saturn V Capital Management LP2,896,588$14.2M
6Portolan Capital Management, LLC2,894,325$14.2M
7VANGUARD CAPITAL MANAGEMENT LLC2,462,757$12.1M
8Vestal Point Capital, LP1,125,000$5.5M
9MILLENNIUM MANAGEMENT LLC1,060,086$5.2M
10GEODE CAPITAL MANAGEMENT, LLC1,035,435$5.1M
11Halter Ferguson Financial Inc.904,051$4.4M
12STATE STREET CORP818,558$4.0M
13HEIGHTS CAPITAL MANAGEMENT, INC775,000$3.8M
14Sands Capital Alternatives, LLC405,837$2.0M
15NORTHERN TRUST CORP323,154$1.6M